TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
The exercise of Warrants Z follows a successfully completed capital increase with preferential subscription rights throu…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
€1.48 million private placement secured from a group of new investors Buyback will mark the end of TME Pharma's converti…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX…
. Median overall survival surpasses 19 months and continues to improve in glioblastoma patients receiving NOX-A12 comb…
L'opération a permis de lever un montant total de 2,7 millions d'euros et d'émettre 10,8 millions d'actions nouvelles. L…